← back to search

Stephen M. Stahl

University of California System · US
🔎 Find collaborators in Psychiatry and Mental health · Pharmacology →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Psychiatry and Mental health · Pharmacology
Research interest
Research interests include Schizophrenia research and treatment, Treatment of Major Depression, Electroconvulsive Therapy Studies, and Pharmacological Effects and Toxicity Studies.
h-index
88
citations
29,864
works
2,570
NIH funding
primary concept
email

Recent publications

Lumateperone for the Treatment of Major Depressive Disorder With Mixed Features or Bipolar Depression With Mixed Features
Journal of Clinical Psychopharmacology 2025cited by 15position: middledoi
Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants
The Journal of Clinical Psychiatry 2024cited by 15position: middledoi
Expert consensus statement for telepsychiatry and attention-deficit hyperactivity disorder
CNS Spectrums 2024cited by 6position: lastdoi
Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions
World Psychiatry 2023cited by 640position: middledoi
Esmethadone-HCl (REL-1017): a promising rapid antidepressant
European Archives of Psychiatry and Clinical Neuroscience 2023cited by 30position: middledoi
Adjunctive agents to antipsychotics in schizophrenia: a systematic umbrella review and recommendations for amino acids, hormonal therapies and anti-inflammatory drugs
BMJ Mental Health 2023cited by 27position: middledoi
Efficacy and safety of selegiline across different psychiatric disorders: A systematic review and meta-analysis of oral and transdermal formulations
European Neuropsychopharmacology 2023cited by 16position: contributordoi
Trazodone once-a-day: A formula for addressing challenges in antidepressant safety and tolerability
Neuroscience Applied 2023cited by 5position: contributordoi
Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic
Trends in Pharmacological Sciences 2022cited by 112position: lastdoi
The prescriber’s guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression
CNS Spectrums 2022cited by 69position: middledoi
Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors
Pharmaceuticals 2022cited by 29position: middledoi
Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling
International Journal of Molecular Sciences 2022cited by 22position: firstdoi
The effect of first- and second-generation antipsychotics on brain morphology in schizophrenia: A systematic review of longitudinal magnetic resonance studies with a randomized allocation to treatment arms
Journal of Psychopharmacology 2022cited by 12position: lastdoi
Neuropsychiatric Consequences of COVID-19 Pandemic: A Synthetic Review from a Global Perspective.
2022cited by 12position: contributordoi
Stahl's Essential Psychopharmacology
Cambridge University Press eBooks 2021cited by 449position: firstdoi
REL-1017 (Esmethadone) Increases Circulating BDNF Levels in Healthy Subjects of a Phase 1 Clinical Study
Frontiers in Pharmacology 2021cited by 27position: middledoi
How and when to treat the most common adverse effects of antipsychotics: Expert review from research to clinical practice.
2021cited by 21position: contributordoi
Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data
Therapeutic Advances in Psychopharmacology 2020cited by 224position: firstdoi
Prescriber's Guide
Cambridge University Press eBooks 2020cited by 53position: firstdoi
The Clozapine Handbook
Cambridge University Press eBooks 2019cited by 215position: lastdoi
Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies
CNS Spectrums 2019cited by 199position: lastdoi
Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity
CNS Spectrums 2019cited by 66position: firstdoi
Expert Consensus on Screening and Assessment of Cognition in Psychiatry
CNS Spectrums 2019cited by 33position: lastdoi
Guidelines for the recognition and management of mixed depression
CNS Spectrums 2017cited by 146position: firstdoi
The pharmacodynamic effects of combined administration of flibanserin and alcohol
Journal of Clinical Pharmacy and Therapeutics 2017cited by 73position: lastdoi
Hypoactive Sexual Desire Disorder
Mayo Clinic Proceedings 2016cited by 224position: middledoi
A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature
European Neuropsychopharmacology 2015cited by 179position: middledoi
Major Depressive Disorder: Understanding the Significance of Residual Symptoms and Balancing Efficacy with Tolerability
The American Journal of Medicine 2015cited by 81position: lastdoi
Modulating the serotonin system in the treatment of major depressive disorder
CNS Spectrums 2014cited by 68position: lastdoi
A randomized, placebo-controlled, double-blind study of sapropterin to treat ADHD symptoms and executive function impairment in children and adults with sapropterin-responsive phenylketonuria
Molecular Genetics and Metabolism 2014cited by 53position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Roger S. McIntyre · Nanjing Medical University6 papers (2017–2025)M. Pappagallo · Università Campus Bio-Medico5 papers (2021–2024)Franco Folli · The University of Texas Health Science Center at San Antonio5 papers (2021–2024) · 5 papers (2021–2024)Sara De Martin · University of Padua5 papers (2021–2024)Charles E. Inturrisi · Stat Medical Devices (United States)5 papers (2021–2024)Maurizio Fava · Massachusetts General Hospital5 papers (2017–2024) · 5 papers (2021–2024) · 4 papers (2013–2020)Andrea Mattarei · University of Padua4 papers (2022–2024)David J. Kupfer · University of Pittsburgh4 papers (2012–2015)Andrea Alimonti · University of Padua4 papers (2022–2024)Luca Pani · University of Modena and Reggio Emilia4 papers (2022–2024)Francesco Bifari · KU Leuven3 papers (2021–2023)Guy M. Goodwin · Newcastle upon Tyne Hospital3 papers (2012–2015)Joshua D. Rosenblat · Canadian Transplant Association3 papers (2017–2023) · 3 papers (2022–2023)Allan H. Young · Kingsley House3 papers (2017–2023) · 3 papers (2021–2023) · 3 papers (2022–2024)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Psychiatry and Mental health · Pharmacology →